Hyphens Pharma International has reported 2HFY2021 earnings of $2.5 million, up 34.6% over the same six months to December period last year. Revenue was up 2.5% y-o-y to $62.1 million.
For the whole of FY2021, earnings increased by 11.1% to $6.8 million, on the back of a 4.1% increase in revenue to $125.9 million.
The company attributes the better numbers to higher sales of both its own proprietary products as well as those that it distributes.
Hyphens Pharma plans to focus more on growing sales of its own products, sold under brands such as Ocean Health, Ceradan, TDF and CG 210.
The company plans to pay a first and final dividend of 0.67 cents, slightly improved from 0.62 cents paid for FY2020.
Lim See Wah, the company’s executive chairman and CEO, calls FY2021 report card a “good set” of results.
See also: Trump wins Republican nomination, setting up rematch with Biden
With the completion of acquisitions specifically the Novem Group, he expects the company’s top and bottom line to improve.
Hyphens Pharma shares last traded at 30 cents.
Photo: Albert Chua / The Edge Singapore
